AMEthyst
The assessment of the Medtronic AVE Interceptor Saphenous Vein Graft Filter System. AMEthyst is investigating a device called the Interceptor Plus Coronary Filter System. The Interceptor Plus filter was designed to stop the debris from going down the vein graft during a stent procedure and causing damage to your heart muscle. This study will examine the use of the Interceptor to see if its use may decrease the complications that associated with plaque particles that might break away during the placement of a stent inside a saphenous vein graft.
Research Coordinator: Tammy Snow 336-718-5810
TIMI-38
This study will compare the effectiveness of Prasugrel (study drug) versus Clopidogrel (Plavix) in patients with acute coronary sydrome (a heart attack or heart/chest pain) who are to undergo percutaneous coronary intervention. The goal of the study is to show that Clopidogrel is superior to Plavix by demonstrating a reduction in deaths, future heart attacks, or strokes.
Research Coordinator: Debra Wilson: 336-718-5810
RED-HF
This study is to assess the efficacy of the study drug Darbepoetin alfa to lower mortality and morbidity in heart failure patients with anemia and left ventricular dysfunction.
Research Coordinator: Jill Stone: 336-718-5810
Improve-It
A study to establish the clinical benefit and safety of Vytorin vs. Simvastin in high risk subjects presenting with acute coronary syndrome (a heart attack/chest pain).
Research Coordinator: Debra Wilson 336-718-5810
L-Tap
To evaluate the proportion of treated Dyslipidemia patients achieving LDL-C goals defined by appropriate regional and national guidelines. To evaluate HDL levels in treated Dyslipidemia patients. This is a survey and does not require the administration of placebo, study drug, or any therapeutic intervention.
Research Coordinator: Jill Stone 336-718-5810
PROTECT
Study of the effects of KW-3902 Injectable Emulsion (study drug) on heart failure signs and symptoms and renal function in patients with acute heart failure syndrome and renal impairment who are hospitalized for volume overload and require intravenous diuretic therapy.
Research Coordinator: Sherry Duncan 336-718-5810
Current OASIS
The objective of this study is to determine if high dose of clopidogrel with aspirin is superior to the standard dose of clopidogrel with aspirin in preventing the composite of cardiovascular death, MI or stroke. The patients must present with non-ST segment elevation acute coronary syndrome that are treated with an early invasive strategy with intent to perform PCI as early as possible within 24 hours of randomization.
Research Coordinator: Richard Ney 336-718-5810
Spirit IV
A clinical trial evaluating the investigational device XIENCE V (coronary stent) in subjects with reference vessel diameters (RVD) 2.5 mm to 4.25 mm and lesion lengths <= 28 mm; non-inferiority to FDA-approved commercially available TAXUS® EXPRESS2 Paclitaxel Eluting Coronary Stent System (TAXUS). (NOTE: RVD 2.5 mm to 3.75 mm until 4.0 mm TAXUS is commercially available).
Research Coordinator: Tammy Snow 336-718-5810
FREEDOM
To evaluate if multivessel percutaneous coronary intervention with drug-eluting stents is more or less effective than coronary artery bypass surgery. Patients will be randomized to either receive the stents or bypass surgery.
Research Coordinator: Richard Ney 336-718-5810
PLATO
The primary objective of this study is to test the hypothesis that AZD6140 (study drug) is superior to clopidogrel (Plavix) for the prevention of vascular events in patients with non-ST or ST elevation acute coronary syndrome (ACS).
Research Coordinator: Richard Ney: 336-718-5810
PERSEUS
A drug eluting stent trial through Boston Scientific focusing on large and small vessels.
Research Coordinator: Tammy Snow 336-718-5810
TOPCAT
To determine if treatment with spironolactone can produce a clinically meaningful reduction in cardiovascular mortality, aborted cardiac arrest or hopitaliztion for the management of heart failure, compared with placebo, in adults with heart failure and left ventricular ejection fraction of at least 45%.
Research Coordinator: To be determined: 336-718-5810
